OKUR OnKure Therapeutics, Inc.
P/E
--
Forward P/E
--
Price/Sales
--
Beta
0.754
Div Yield
--
Market Cap
--
Company Analysis
Latest News
OnKure Therapeutics reports third quarter 2026 EPS loss of $0.36 and extends cash runway
OnKure Therapeutics reported zero revenue and a net loss of $17.8 million for the third quarter of 2026. While the EPS loss of $0.36 missed analyst estimates...
OnKure Therapeutics, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
For the third quarter of 2026, OnKure Therapeutics is expected to report a consensus EPS loss of $0.29 on zero revenue, with its current $18.25 share price...